{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:52:22Z","timestamp":1791939142489,"version":"4.3.4"},"reference-count":80,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,2,1]]},"abstract":"<jats:p> PURPOSE: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). <\/jats:p><jats:p> PATIENTS AND METHODS: Adults with newly diagnosed ALL referred since 1992 were entered onto the study; treatment was initiated in 204 patients between 1992 and January 1998. No exclusions were made because of older age, poor performance status, organ dysfunction, or active infection. Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in 17%. Leukocytosis of more than 30 \u00d7 10<jats:sup>9<\/jats:sup>\/L was found in 26%, Philadelphia chromosome\u2013positive disease in 16% (20% of patients with assessable metaphases), CNS leukemia at the time of diagnosis in 7%, and a mediastinal mass in 7%. Treatment consisted of four cycles of Hyper-CVAD alternating with four cycles of high-dose methotrexate (MTX) and cytarabine therapy, together with intrathecal CNS prophylaxis and supportive care with antibiotic prophylaxis and granulocyte colony-stimulating factor therapy. Maintenance in patients with nonmature B-cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP). <\/jats:p><jats:p> RESULTS: Overall, 185 patients (91%) achieved complete remission (CR) and 12 (6%) died during induction therapy. Estimated 5-year survival and 5-year CR rates were 39% and 38%, respectively. The incidence of CNS relapse was low (4%). Compared with 222 patients treated with vincristine, doxorubicin, and dexamethasone (VAD) regimens, our patients had a better CR rate (91% v 75%, P &lt; .01) and CR rate after one course (74% v 55%, P &lt; .01) and better survival (P &lt; .01), and a smaller percentage had more than 5% day 14 blasts (34% v 48%, P = .01). Previous prognostic models remained predictive for outcome with Hyper-CVAD therapy. <\/jats:p><jats:p> CONCLUSION: Hyper-CVAD therapy is superior to our previous regimens and should be compared with established regimens in adult ALL. <\/jats:p>","DOI":"10.1200\/jco.2000.18.3.547","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:04:24Z","timestamp":1487919864000},"page":"547-547","source":"Crossref","is-referenced-by-count":701,"title":["Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia"],"prefix":"10.1200","volume":"18","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Huh","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul S.","family":"Ha","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil J.","family":"Freireich","sequence":"additional","affiliation":[{"name":"From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children\u2019s Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"R2-0082","doi-asserted-by":"crossref","unstructured":"Pinkel  D:  Curing children of leukemia.  Cancer 60:1683,1987-1691,","DOI":"10.1002\/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G"},{"key":"R3-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.994"},{"key":"R4-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1312"},{"key":"R5-0082","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90028-0"},{"key":"R6-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.123.123"},{"key":"R7-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.6.1014"},{"key":"R8-0082","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30261-2"},{"key":"R9-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.57.57"},{"key":"R10-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"R11-0082","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830080207"},{"key":"R12-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.11.2814.2814"},{"key":"R13-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.58"},{"key":"R14-0082","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90049-3"},{"key":"R15-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.9.2411.2411"},{"key":"R16-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.12.2983.2983"},{"key":"R17-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.3067.3067"},{"key":"R18-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"R19-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"R20-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"R21-0082","doi-asserted-by":"crossref","unstructured":"Fenaux  P,  Lai  JL,  Miaux  O, et al:  Burkitt cell acute leukaemia (L ALL) in adults:  A report of 18 cases. Br J Haematol 71:371,1989-376,  3","DOI":"10.1111\/j.1365-2141.1989.tb04294.x"},{"key":"R22-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"R23-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.941"},{"key":"R24-0082","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401065"},{"key":"R25-0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151101"},{"key":"R26-0082","unstructured":"Pui  C-H,  Simone  JV,  Hancock  ML, et al:  Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children:  Long-term results of St Jude total therapy study X. Leukemia 6:150,1992-157,"},{"key":"R27-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.8.1442"},{"key":"R28-0082","doi-asserted-by":"crossref","unstructured":"Camitta  B,  Leventhal  B,  Lauer  S, et al:  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood:  A Pediatric Oncology Group study. J Clin Oncol 10:1539,1989-1544,","DOI":"10.1200\/JCO.1989.7.10.1539"},{"key":"R29-0082","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90733-6"},{"key":"R30-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.527"},{"key":"R31-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"R32-0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291810"},{"key":"R33-0082","unstructured":"Bassan  R,  Lerede  T,  Barbui  T:  Institutional performance and dose intensity as prognostic factors in adult ALL.  Leukemia 9:933,1995-936,"},{"key":"R34-0082","unstructured":"Todeschini  G,  Meneghini  V,  Pizzolo  G, et al:  Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.  Leukemia 8:376,1994-381,"},{"key":"R35-0082","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400912"},{"key":"R36-0082","unstructured":"Chiu  EKW,  Chan  LC,  Liang  R, et al:  Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia:  A possible dose effect. Leukemia 8:1469,1994-1473,"},{"key":"R37-0082","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695970"},{"key":"R38-0082","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<2950::AID-CNCR2820721015>3.0.CO;2-B"},{"key":"R39-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.4.876.876"},{"key":"R40-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.444.bloodjournal862444"},{"key":"R41-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.2.590"},{"key":"R42-0082","unstructured":"Ottmann  OG,  Hoelzer  D:  Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia?  Leukemia 10:1111,1996-1116,"},{"key":"R43-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.8.3143.bloodjournal8783143"},{"key":"R44-0082","unstructured":"Larson  RA,  Dodge  RK,  Linker  CA, et al:  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia:  CALGB Study 9111. Blood 92:1556,1998-1564,"},{"key":"R45-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.4.1025.1025"},{"key":"R46-0082","unstructured":"Campos  L,  Sabido  O,  Sebban  C, et al:  Expression of -2 proto-oncogene in adult acute lymphoblastic leukemia.  Leukemia 10:434,1996-438,  BCL"},{"key":"R47-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140"},{"key":"R48-0082","doi-asserted-by":"publisher","DOI":"10.1007\/BF01757343"},{"key":"R49-0082","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb02684.x"},{"key":"R50-0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241204"},{"key":"R52-0082","unstructured":"Preti  A,  Kantarjian  HM,  Estey  E, et al:  Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.  Hematol Pathol 8:155,1994-167,"},{"key":"R53-0082","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951101)76:9<1564::AID-CNCR2820760911>3.0.CO;2-1"},{"key":"R54-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2370"},{"key":"R55-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.5.1784.1784"},{"key":"R56-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091"},{"key":"R58-0082","doi-asserted-by":"crossref","unstructured":"Kaplan  FL,  Meier  P:  Nonparametric estimation from incomplete observations.  J Am Stat Assoc 52:457,1958-481,","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R59-0082","unstructured":"Mantel  N:  Evaluation of survival data and two new rank order statistics arising in its consideration.  Cancer Chemother Rep 50:163,1966-170,"},{"key":"R60-0082","doi-asserted-by":"crossref","unstructured":"Cox  DR:  Regression models and life tables.  J R Stat Soc B 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R61-0082","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"R62-0082","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/77.1.147"},{"key":"R63-0082","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"R64-0082","unstructured":"Uckun  FM,  Sather  HN,  Gaynon  PS, et al:  Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia:  A report from the Children\u2019s Cancer Group. Blood 90:28,1997-35,"},{"key":"R65-0082","doi-asserted-by":"crossref","unstructured":"Putti  MC,  Rondelli  R,  Cocito  M-G, et al:  Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia:  Italian experience in AIEOP-ALL 88-91 studies. Blood 9:795,1998-801,","DOI":"10.1182\/blood.V92.3.795"},{"key":"R66-0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.411"},{"key":"R67-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"R68-0082","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149129"},{"key":"R69-0082","unstructured":"Frankel  SR,  Kurtzberg  J,  Deoleivera  D, et al:  Toxicity and pharmacokinetics of PEG-asparaginase in newly-diagnosed adult acute lymphoblastic leukemia:  CALGB 9511. Blood 88:669a,1996  (suppl 1, abstr)"},{"key":"R70-0082","unstructured":"Kurtzberg  J,  Keating  M,  Moore  JO, et al:  2-Amino-9-B-arabinosyl-6-methoxy-9H-guanine (GW506U;Compound 506U) is highly active in patients with T-cell malignancies:  Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood 88:699a,1996  (abstr)"},{"key":"R71-0082","unstructured":"Beran  M,  Cao  X,  Estrov  Z, et al:  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).  Clin Cancer Res 4:1661,1998-1672,  r"},{"key":"R72-0082","unstructured":"Druker  BJ,  Sawyers  CL,  Talpaz  M, et al:  Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients.  Proc Am Soc Clin Oncol 18:7a,1999  (abstr 24)"},{"key":"R73-0082","unstructured":"Thomas  D,  Kantarjian  H,  O\u2019Brien  S, et al:  Outcome with the Hyper-CVAD regimen in lymphoblastic lymphoma (LL).  Proc Am Soc Clin Oncol 18:11a,1999  (abstr 38)"},{"key":"R74-0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802193380803"},{"key":"R75-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.246"},{"key":"R76-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.345"},{"key":"R77-0082","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880401)61:7<1292::AID-CNCR2820610703>3.0.CO;2-O"},{"key":"R78-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.587"},{"key":"R79-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1826"},{"key":"R80-0082","doi-asserted-by":"crossref","unstructured":"Thomas  D,  Cortes  J,  O\u2019Brien  S, et al:  Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia.  J Clin Oncol 17:2461,1990-2470,","DOI":"10.1200\/JCO.1999.17.8.2461"},{"key":"R81-0082","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2"},{"key":"R82-0082","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.3.547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:38:47Z","timestamp":1653514727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.3.547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,2,1]]}},"alternative-id":["10.1200\/JCO.2000.18.3.547"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.3.547","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,1]]}}}